C12N 2760/10034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/10034 (Use of virus or viral component as vaccine) appears on 57 US grants and 123 published applications in this corpus.
Search patents in C12N- Granted patents
- 57
- Published applications
- 123
- Assignees
- 62
- Inventors
- 218
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 2 |
| 2004 | 1 | 1 |
| 2005 | 1 | 1 |
| 2006 | 2 | 4 |
| 2007 | 1 | 0 |
| 2008 | 1 | 1 |
| 2009 | 1 | 1 |
| 2010 | 1 | 5 |
| 2011 | 1 | 3 |
| 2012 | 0 | 6 |
| 2013 | 2 | 1 |
| 2014 | 3 | 6 |
| 2015 | 1 | 4 |
| 2016 | 2 | 5 |
| 2017 | 4 | 5 |
| 2018 | 3 | 6 |
| 2019 | 1 | 8 |
| 2020 | 5 | 7 |
| 2021 | 2 | 10 |
| 2022 | 6 | 10 |
| 2023 | 6 | 7 |
| 2024 | 5 | 8 |
| 2025 | 5 | 13 |
| 2026 | 1 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Lassavirus vaccines24 Feb 2026US 12,558,410 B2Katholieke Universiteit Leuven
- Activation of resident memory T cells for cancer immunotherapy23 Dec 2025US 12,502,406 B2Regents of the University of Minnesota
- Nanoparticle vaccines with novel structural components21 Oct 2025US 12,447,206 B2The Scripps Research Institute
- Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)29 Jul 2025US 12,370,249 B2GeoVax, Inc.
- HBV vaccines and methods treating HBV22 Jul 2025US 12,364,751 B2Gilead Sciences, Inc.
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Activation of resident memory t cells for cancer immunotherapy28 May 2026US 2026/0144820 A1New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
- Novel vsv virus formulations7 May 2026US 2026/0124288 A1Emergent Product Development Gaithersburg Inc.
- Tri-segmented pichinde viruses as vaccine vectors23 Apr 2026US 2026/0109736 A1Hookipa Biotech GmbH
Most cited
By later US patents
- Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use44US 7,517,520 B2Cytos Biotechnology AG · 2009
- Method of inducing a CTL response42US 6,977,074 B2MannKind Corporation · 2005
- Antigen delivery system32US 6,306,387 B1The Research Foundation of State University of New York · 2001
- Method of inducing a CTL response28US 6,994,851 B1MannKind Corporation · 2006
- Synthetic viruses and uses thereof22US 8,673,612 B2L'Universite Pierre Et Marie Curie · 2014